What the molecule is
GHK is a tripeptide: glycyl-L-histidyl-L-lysine. Its histidine residue binds copper(II) with high affinity, and the resulting complex is what GHK-Cu refers to. The copper is not an additive — it is integral to the molecule's proposed activity.
GHK occurs naturally in human plasma, and its concentration is reported to decline substantially with age. That observation is the origin of most interest in it, and it is an observation rather than a demonstrated causal relationship with anything.
Two very different contexts
Topically, GHK-Cu is an established cosmetic ingredient. It appears in commercially available skincare products in many markets, regulated under cosmetic frameworks, with published work on skin appearance endpoints. This is legal, ordinary and unremarkable.
Injected, it is a different proposition entirely. There is no regulatory approval for injectable GHK-Cu in any major jurisdiction, no established clinical evidence base for systemic administration, and the safety profile of introducing a copper-binding compound systemically is not characterised in the way an approved medicine's would be.
The two are frequently blurred together, with the cosmetic evidence and regulatory acceptance invoked to support the injectable case. They do not transfer. A compound applied to the skin surface and a compound delivered into the bloodstream are different questions even when the molecule is identical.
| Topical | Injected | |
|---|---|---|
| Regulatory status | Established cosmetic ingredient | No approval in major jurisdictions |
| Evidence base | Published work on skin endpoints | Not established |
| Availability | Ordinary retail | Research-labelled supply only |
What the research examines
The published literature covers copper's established role as a cofactor in enzymes involved in collagen and elastin cross-linking, in vitro work on gene expression relating to extracellular matrix components, and studies of skin appearance following topical application.
Work relating to wound healing and tissue remodelling exists largely in animal and laboratory models. As with most compounds in this category, the leap from that literature to conclusions about systemic administration in humans is one the literature itself does not make.
Key takeaways
- GHK-Cu is a copper-bound tripeptide that occurs naturally in plasma and declines with age.
- Topical cosmetic use is mainstream and regulated; injectable use has no approval anywhere.
- Evidence from the topical context does not transfer to the injectable one, though it is routinely invoked as though it does.
- The copper is integral to the molecule, not an additive.
Stop keeping this in your head.
Pep AI keeps your compounds, vials, schedule, injection sites and history in one place — and does the reconstitution math for you. Free on iOS and Android.
Frequently asked questions
Keep reading
This guide is general information for people already organising their own protocol. It is not medical advice, it does not recommend any compound or dose, and Pep AI is not a medical device. Talk to a qualified healthcare professional about anything you inject.
Published by the Pep AI team · Updated August 2026